Cite

HARVARD Citation

    Roy, B. et al. (2022). A Structured Benefit-Risk Assessment to Evaluate a Combination of Olanzapine and Samidorphan for the Treatment of Schizophrenia and Bipolar I Disorder. CNS spectrums. p. 233. [Online]. 
  
Back to record